Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BM...
June 16 2020 - 6:30AM
Heidelberg, Germany, June 16, 2020 – Affimed
N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer, today announced that it will release first quarter 2020
results on Tuesday, June 23, 2020 and host a conference call at
8:30 a.m. EDT to discuss financial results and recent corporate
developments.
The conference call will be available via phone and webcast. To
access the first quarter results call, please dial +1-646-741-3167
for U.S. callers, or +44 (0) 2071 928338 for international callers,
and reference conference ID 8594214 approximately 15 minutes prior
to the call.
To access the live audio webcast of the conference call please
visit the “Investors” section of company’s website at
https://www.affimed.com/investors/webcasts_cp/. A replay of the
call will be archived on the Affimed website for 30 days after the
call.
BMO Conference Participation
Affimed also announced that its Chief Executive Officer, Dr. Adi
Hoess, will participate in a fireside chat at the 2020 BMO
Prescriptions for Success Healthcare Conference on Tuesday, June
23, at 1:30 p.m. EDT.
A live webcast of the fireside chat will be available on the
“Investors” section of the company’s website at
https://www.affimed.com/investors/webcasts_cp?/. A replay of the
fireside chat will be archived on the Affimed website for 30 days
following the event.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer. Affimed’s fit-for-purpose ROCK® platform allows
innate cell engagers to be designed for specific patient
populations. The company is developing single and combination
therapies to treat hematologic and solid tumors. The company is
currently enrolling patients into a registration-directed study of
AFM13 for CD30-positive relapsed/refractory peripheral T cell
lymphoma and into a Phase 1/2a dose escalation/expansion study of
AFM24 for the treatment of advanced EGFR-expressing solid tumors.
For more information, please visit www.affimed.com.
Investor & Media Contact:
Alex FudukidisHead of Investor RelationsE-Mail:
a.fudukidis@affimed.comTel: (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024